CDB Global Announces Change of Chief Financial Officer

DENVER, CO, April 26, 2022 (GLOBE NEWSWIRE) — via NewMediaWire — CBD Global Sciences Inc., dba Global Sciences Inc. (OTC: CBDNF) (CSE: CBDN) (Frankfurt: GS3.F) (Munich: GS3 .MU ) (the “Company”) announced that Mr. Alexander McAulay has tendered his resignation as the Company’s Chief Financial Officer (“CFO”) effective April 14, 2022.

The Company also announced that Mr. Glenn Dooley has been appointed interim Chief Financial Officer of the Company effective April 14, 2022. Mr. Dooley is also a director and chief operating officer of the company. He co-founded Strasburg Pharms, LLC, SMBT, LLC and CannaOil, Inc., all wholly owned subsidiaries of Global NV. He is also a co-founder/co-owner, broker and chief operating officer of MAC5 Mortgage, Inc., which he co-founded in 2006 with Brad Wyatt.

ABOUT GLOBAL SCIENCES INC.

CBD Global Sciences, Inc., dba Global Sciences Inc. has grown into a multifaceted company focused on harnessing the industrial hemp plant to create healthier lifestyles. His website can be found at www.globalsciences.ca. Global Sciences, Inc. is a hemp-based CBD producer and branding investment vehicle that currently owns multiple brands such as Aethics™ www.aethics.com and CANNAOIL™ www.cannaoilshop.com and CBD oil tinctures (liquid products) and CBD offers capsules, CBD topicals, hydration products, and confectionery. Global Sciences hemp-derived CBD extracts are sold online through select distributors and brick-and-mortar retailers.

Through its wholly owned subsidiaries, Global Sciences Holdings, Resinosa LLC, www.resinosa.com, and Legacy Distribution Group, www.legacydistributiongroup.com, Global Sciences supplies high-quality CBD products in retail and e-commerce formats nationwide. The Direct Store Delivery (DSD) provides distribution services for multiple suppliers of CBD-infused products and non-CBD products in the Colorado and Wyoming areas, serving over 750 C-stores and large box retailers with expansion plans to more than 5,000 stores in the next 12-24 months. In addition to Legacy Distribution, it has a manufacturing division, Resinosa LLC www.Resinosa.com, with its capabilities to provide cGMP manufacturing for the CBD industry with both private label and white label CBD and non-CBD product lines.

For more information, please contact Investor Relations at 720-881-2541 or email [email protected] Additional information about Global Sciences is also available at www.globalsciences.ca.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATORY SERVICE PROVIDER HAS REVIEWED THE ADEQUACY OR ACCURACY OF THIS NOTICE OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS NOTICE.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION: This press release contains certain “forward-looking statements” under applicable Canadian securities laws. Forward-looking statements include, but are not limited to, statements regarding future developments and the Company’s business and operations. Forward-looking statements are necessarily based on a number of estimates and assumptions that, while believed to be reasonable, are subject to known and unknown risks, uncertainties and other factors that could cause actual results and future events to differ materially from those expressed or implied deviate from such forward-looking statements. These factors include, among others, general business, economic, competitive, political and social uncertainties; and delay or failure to receive board, shareholder or regulatory approvals. Readers should not place undue reliance on forward-looking statements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.